Cardiol Therapeutics Inc. Class A Common Shares (CRDL)

FairStock Score: 33/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-and-Buffett-style investor, I start with what is knowable. Cardiol is an 18-employee, clinical-stage life-sciences company focused on anti-fibrotic and anti-inflammatory heart therapies; its lead candidate is in a Phase III study. That is a serious area, but there is no commercial product and no demonstrated competitive moat yet. The provided data show revenue growth as N/A, trailing free cash flow of -$24.1M, and a -15.0% FCF yield on a $160.3M market cap. Financial health is mixed: D/E is 0.00, and the FairStock Altman Z-Score is 8.06, but the Piotroski F-Score is only 2/9. Returns are deeply negative—FairStock ROE -190.18% and ROCE -90.92%—so book value is not earning its keep. Valuation is hard to anchor because the FairStock P/E is -4.67 on losses; the $1.12 close on 2026-10-26 gives a P/B of 7.47, which is rich for a company with negative returns. A 33/100 FairStock score and no Lynch category due to only zero years of filed results reinforce that this is a speculative clinical story, not a proven compounding business. The growth trajectory hinges on trial outcomes and cash funding, not on current earnings power. I would want either a lower price or clear evidence that the Phase III asset can become a durable commercial product before the numbers offer a margin of safety.

In plain English: Cardiol Therapeutics is a small drug company testing treatments for heart inflammation and scarring; it has no commercial revenue shown and depends on trial progress. The finances look weak because it is burning cash and has deeply negative returns, though it has no debt. At $1.12 a share on 2026-10-26, the $160.3 million market value looks expensive relative to current accounting value, so the price is not supported by today's numbers alone.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer